MB-CART19.1

Phase 2Cell therapy

MB-CART19.1 is one of 23 biologic programs targeting Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaNot yet recruiting

RefractoryRecruiting

Acute Lymphoblastic Leukemia RecurrentActive, not recruiting

Long-Term Follow-upRecruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaPreclinical

Not yet recruiting

RefractoryPhase 2

Recruiting

Acute Lymphoblastic Leukemia RecurrentPhase 1

Active, not recruiting

Long-Term Follow-upPreclinical

Recruiting

Competition

Competitive Landscape

26 competitors in Refractory

#DrugCompanyPhaseTrials

Nplate

Amgen

Phase 3

2 2

Jakafi

Incyte

Phase 2

2 3

Blincyto

Amgen

Phase 1

1 4

Gecacitinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2

1 5

Maat013

MMaaT Pharma

Phase 3

1 6

Tavalisse

RRigel Pharmaceuticals

Phase 1

1 7

MB-CART19.1

MMiltenyi Biomedicine GmbH

Phase 2

1 8

Flomax

Sanofi

Preclinical

1 9

CD19 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 1

3 10

CAR-T Therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Refractory

NCT06189157

Q4 2029

PreclinicalNot yet recruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT07890025

Q4 2040

PreclinicalRecruiting

Melanoma Stage III

NCT06508775

Clinical

Trials by Indication[1]

Refractory1 trial

MB-CART19.1 in Refractory SLE

Recruiting·MMiltenyi Biomedicine GmbH·Phase 1/2·NCT06189157·29 enrolled

CAR1 trial

MB-CART19.1 in Patients With R/R ALL

Unknown status·SShanghai Children's Medical Center·Phase 2·NCT03321123·10 enrolled

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia1 trial

An Open-Label, Single-Center, Phase I/II Study Evaluating the Safety and Efficacy of a CAR T Cell Therapy Targeting CD19, in Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Not yet recruiting·HHospital Universitario Dr. Jose E. Gonzalez·Preclinical·NCT07890025·30 enrolled

Melanoma Stage III1 trial

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Recruiting·MMiltenyi Biomedicine GmbH·Preclinical·NCT06508775·40 enrolled

Acute Lymphoblastic Leukemia Recurrent1 trial

A Phase I Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies

Active, not recruiting·MMiltenyi Biomedicine GmbH·Phase 1·NCT03853616·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MB-CART19.1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MB-CART19.1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MB-CART19.1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Miltenyi Biomedicine GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: MMiltenyi Biomedicine GmbH

MB-CART19.1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Q4 2040

Trials by Indication[1]

Refractory1 trial

CAR1 trial

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia1 trial

Melanoma Stage III1 trial

Acute Lymphoblastic Leukemia Recurrent1 trial

References

Drug Info

Quick Facts

Related News